SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

BNB (BNB) is a cryptocurrency . BNB has a current supply of 131,511,348.93. The last known price of BNB is 702.2705794 USD and is down -0.19 over the last 24 hours. It is currently trading on 3523 active market(s) with $1,103,086,320.06 traded over the last 24 hours. More information can be found at https://bnbchain.org/en.

Binance

Discussion centers on a reported major Binance security breach and withdrawal disruptions, raising concerns about customer fund safety and the exchanges solvency. Traders debate the reported North Korea-linked attribution against speculation about an inside job, while some cite Binances assurances that losses will be covered.

ZIM Integrated Shipping Services Ltd. engages in the provision of shipping and logistics services. It offers shipping solutions, including the transportation of out-of-gauge cargo, refrigerated cargo, and dangerous and hazardous cargo. The company was founded on June 7, 1945 and is headquartered in Haifa, Israel.

Zim Integrated Shipping Services Ltd

ZIMs raised full-year outlook, supported by strong freight rates and demand, is fueling discussion about earnings and potential dividends. Traders are also debating the uncertain Hapag-Lloyd takeover and whether a standalone company could return more value to shareholders, with some caution over insider selling and deal risk.

Hedera (HBAR) is a cryptocurrency launched in 2017. Hedera has a current supply of 50,000,000,000 with 44,327,154,878.82761615 in circulation. The last known price of Hedera is 0.07180731 USD and is down -0.57 over the last 24 hours. It is currently trading on 465 active market(s) with $36,939,739.82 traded over the last 24 hours. More information can be found at https://www.hedera.com/.

Hedera Hashgraph

HBAR is drawing attention amid a prolonged pullback toward the seven-cent area, with traders debating whether continued weakness reflects broader crypto-market pressure and persistent sell supply or presents a buying opportunity. Some holders are accumulating and citing Hederas enterprise and AI use cases, while skeptics point to weak price performance and rallies that have reversed; no single confirmed new catalyst dominates the discussion.

Occidental Petroleum Corp. engages in the exploration and production of oil and natural gas. It operates through the following segments: Oil and Gas, Chemical, and Midstream and Marketing. The Oil and Gas segment explores for, develops and produces oil and condensate, natural gas liquids, and natural gas. The Chemical segment manufactures and markets basic chemicals and vinyls. The Midstream and Marketing segment purchases, markets, gathers, processes, transports and stores oil, condensate, natural gas liquids, natural gas, carbon dioxide, and power. The company was founded in 1920 and is headquartered in Houston, TX.

Occidental Petroleum Corp.

OXY is drawing attention around oil-supply headlines, including OPEC+ keeping production targets steady and ongoing concern about Iran-related disruptions to shipping and exports. Traders are watching a potential breakout and call-heavy options activity, while others question how reliably the shares track crude prices.

Tidal Trust II - YieldMax MSTR Option Income Strategy ETF

YieldMax MSTR Option Income Strategy ETF

MSTYs sharp decline is drawing attention to its exposure to MSTR and Bitcoin, alongside concerns about NAV erosion and shrinking weekly distributions from its option-income strategy. Holders are split between buying the dip for income and betting on a crypto recovery, while critics warn the price and payouts may keep deteriorating and raise the prospect of another reverse split.

Fiserv, Inc. engages in the provision of financial services technology. It operates through the Merchant and Financial segments. The Merchant segment offers commerce-enabling products and services including merchant acquiring and digital commerce and mobile payment services, and security and fraud protection, stored-value, and pay-by-bank solutions to companies of all sizes. The Financial segment provides products and services such as processing of customer loan and deposit accounts, digital payments, and card transactions to financial institutions and corporate and public sector clients. The company was founded by Leslie M. Muma and George D. Dalton on July 31, 1984 and is headquartered in Milwaukee, WI.

Fiserv, Inc.

Fiservs earnings miss and reduced 2026 outlook are driving debate, with traders focused on weaker business performance and doubts about managements execution. Some see the sharp selloff as a value opportunity and point to turnaround potential, while speculation about asset sales and a recovery remains unconfirmed.

Twilio, Inc. engages in the development of communications software, cloud-based platforms, and services. It operates through Twilio Communications and Twilio Segments. The Twilio Communications segment includes the platforms Messaging and Voice. The Twilio Segment involves Segment, Engage, Flex, Email, and others. The company was founded by John Wolthuis, Jeffery G. Lawson, and Evan Cooke in March 2008 and is headquartered in San Francisco, CA.

Twilio Inc - Ordinary Shares Class A

Twilio Inc

Twilios quarterly beat and raised full-year outlook were overshadowed by softer Q4 organic-growth guidance, which signaled a slowdown and fueled a sharp post-earnings selloff. Traders debate whether the drop reflects justified concern about decelerating growth or an overreaction to otherwise strong results, with some watching for support and a bounce.

Stellar (XLM) is a cryptocurrency launched in 2014. Stellar has a current supply of 50,001,786,837.39707 with 35,251,444,473.510925 in circulation. The last known price of Stellar is 0.16965209 USD and is down -0.50 over the last 24 hours. It is currently trading on 848 active market(s) with $69,462,156.70 traded over the last 24 hours. More information can be found at https://www.stellar.org.

Stellar Lumens

XLMs persistent selloff and failure to hold recent levels dominate the discussion, with many traders blaming heavy token supply or broader crypto weakness; claims of ongoing Stellar Foundation selling are speculation. Bulls are buying dips and pointing to DTCC and other tokenization developments, while skeptics argue those adoption stories have not translated into price strength.

Arm Holdings Plc engages in the licensing, marketing, research, and development of microprocessors, systems IP, graphics processing units, physical IP and associated systems IP, software, and tools. It operates through the following geographical segments: United Kingdom, United States, and Other Countries. The company was founded on November 12, 1990 and is headquartered in Cambridge, the United Kingdom.

Arm Holdings plc. - ADR

Arm Holdings Plc.

A sharp selloff in ARM and other semiconductor stocks has traders debating whether the decline is an oversold pullback or a deeper repricing, with some blaming weakness across chipmakers and others pointing to ARMs rich valuation and negative momentum. Dip buyers cite the long-term AI and CPU-demand story, while bears expect more downside.

Magnite, Inc. provides a technology solution to automate the purchase and sale of digital advertising inventory for buyers and sellers. It features applications and services for digital advertising sellers including websites, mobile applications, and other digital media properties. The company was founded by Frank Addante, Duc Chau, Craig Roah, Julie Mattern and Brian D. Baumgart on April 20, 2007 and is headquartered in New York, NY.

Magnite Inc

Attention centers on anticipation for Magnites next earnings report, with traders looking for confirmation that connected-TV advertising can sustain growth. Views are split between dip-buyers expecting strong results and concern over recent weakness, broader ad-tech pressure, and uncertainty around digital advertisings outlook.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Why Is GANX Stock Rallying 22% After Hours?

Equity

The U.S. Food and Drug Administration (FDA) cleared Gain Therapeutics to begin a mid-stage clinical trial of its experimental drug GT-02287 in people with Parkinson’s disease.


12 Health Care Stocks Moving In Monday's After-Market Session

Gainers

Gain Therapeutics (NASDAQ:GANX) stock rose 20.2% to $2.38 during Monday's after-market session. The market value of their outstanding shares is at $74.6 million.
BNB Plus (NASDAQ:BNBX) stock rose 9.78% toread more...

Gain Therapeutics (NASDAQ:GANX) Stock Price Up 1.1% - Here's Why

Gain Therapeutics (NASDAQ:GANX) Stock Price Up 1.1% - Here's Why...

Gain Therapeutics, Inc. (NASDAQ:GANX) Receives Consensus Recommendation of "Moderate Buy" from Analysts

Gain Therapeutics, Inc. (NASDAQ:GANX - Get Free Report) has been given a consensus recommendation of "Moderate Buy" by the five research firms that are currently covering the firm, MarketBeat...

HC Wainwright Has Positive Estimate for GANX Q1 Earnings

Gain Therapeutics, Inc. (NASDAQ:GANX - Free Report) - HC Wainwright raised their Q1 2026 earnings estimates for Gain Therapeutics in a research note issued on Monday, March 30th. HC Wainwright...

Gain Therapeutics (NASDAQ:GANX) Issues Earnings Results

Gain Therapeutics (NASDAQ:GANX - Get Free Report) issued its earnings results on Thursday. The company reported ($0.11) EPS for the quarter, beating the consensus estimate of ($0.14) by $0.03...

Gain Therapeutics Highlights GT-02287 Biomarker Signals, Eyes Phase 2 Start in Q3 at Roth Conference

Gain Therapeutics (NASDAQ:GANX) is developing oral small-molecule drugs aimed at neurodegenerative diseases, with its lead focus on Parkinson's disease, company CEO Gene Mack said during a fireside...

Gain Therapeutics (GANX) Expected to Announce Earnings on Thursday

Gain Therapeutics (NASDAQ:GANX) will be releasing its Q4 2025 earnings before the market opens on Thursday, March 26. (View Earnings Report at...

Gain Therapeutics (NASDAQ:GANX) Trading Up 3.7% - What's Next?

Gain Therapeutics (NASDAQ:GANX) Stock Price Up 3.7% - Should You Buy...

Gain Therapeutics, Inc. (NASDAQ:GANX) Receives Consensus Recommendation of "Moderate Buy" from Brokerages

Gain Therapeutics, Inc. (NASDAQ:GANX - Get Free Report) has been assigned a consensus rating of "Moderate Buy" from the seven analysts that are presently covering the firm, Marketbeat reports. One...

Gain Therapeutics, Inc. is a redefining drug discovery company, which identifies and optimizes allosteric binding sites that never targeted before. Its See-Tx target identification platform uses the published 3D structure of enzymes and a proprietary computational technology to discover new allosteric binding sites and predict their druggability. The firm is also unlocking new treatment options to treat disorders characterized by protein misfolding. The company was founded by Khalid Islam in 2017 and is headquartered in Bethesda, MD.

Gain Therapeutics Inc

Bearish Sentiment

<ul class="summary-bullets"><li>The decision allows the Bethesda, Maryland-based biotech to expand testing into the United States, with the study expected to start in the third quarter of this year.</li><li>GT-02287 is Gain’s lead drug candidate and the first product from its Magellan AI drug-discovery platform to reach this stage of development.</li><li>Current Parkinson’s treatments mainly ease symptoms such as tremors and stiffness but do not stop the underlying damage to brain cells.</li></ul>Shares of Gain Therapeutics (GANX) jumped 21% after hours on Monday after the company announced that the U.S. Food and Drug Administration has cleared the company to begin a mid-stage clinical trial of its experimental drug GT-02287 in people with Parkinson’s disease.The decision allows the Bethesda, Maryland-based biotech to expand testing into the United States, with the study expected to start in the third quarter of this year. The move follows encouraging results from earlier early-stage studies conducted in Australia.The trials conducted in Australia showed the drug was generally safe and well-tolerated in both healthy volunteers and Parkinson’s patients. Researchers also observed signs that the drug engaged its intended target in the brain, along with early hints of clinical benefit. Some participants reported improvements in sense of smell and taste, balance, gait, and sleep, as per the company.<h2 class="st-heading-2">What Will The New Study Test?</h2>The upcoming Phase 2 trial will evaluate oral GT-02287 in people with early Parkinson’s disease, including those who carry a common genetic risk factor known as a GBA1 mutation. Sites in the United States, Australia, and select European centers will take part. The study aims to further assess safety while looking for clearer signals of whether the drug can improve symptoms and slow disease progression.GT-02287 is Gain’s lead drug candidate and the first product from its Magellan AI drug-discovery platform to reach this stage of development. The company has built much of its Parkinson’s program around this single molecule, supported by grants from major research organizations, including The Michael J. Fox Foundation. All of the company’s remaining programs are in early discovery or preclinical research phase, without yet entering human trials.Current Parkinson’s treatments mainly ease symptoms such as tremors and stiffness but do not stop the underlying damage to brain cells. GT-02287 is designed to help restore the function of a key enzyme that becomes impaired in many Parkinson’s patients. Preclinical work and early human data suggest the drug may reduce toxic protein buildup and inflammation linked to the disease, raising hopes it could eventually slow or halt progression rather than just manage symptoms.<h2 class="st-heading-2">How Did GANX Retail Traders React?</h2>On Stocktwits, retail sentiment around GANX jumped from ‘bearish’ to ‘bullish’ over the past 24 hours, while message volume rose from ‘normal’ to ‘high’ levels.A Stocktwits user voiced hopes in the drug’s potential to reverse Parkinson’s symptoms.<stembedurl>https://www.stocktwits.com/MQuick/message/657842752</stembedurl>Another compared Gain’s drug with Roche’s prasinezumab, which also aims to slow or stop the progression of Parkinson's. Roche is currently undertaking late-stage trials for the drug.<stembedurl>https://www.stocktwits.com/microcapspeculator/message/657842115</stembedurl><a href="https://stocktwits.com/symbol/GANX">GANX stock</a> has fallen by about 39% year-to-date.&nbsp;Read More: <a href="https://stocktwits.com/news-articles/markets/equity/uber-stock-drops-after-waymo-robotaxis-reportedly-disappear-from-robotaxi-app/cZ19mzBR7Ll">UBER Stock Drops After Waymo Robotaxis Reportedly Disappear From Phoenix App</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Rising stock market chart on a trading board background.

The U.S. Food and Drug Administration (FDA) cleared Gain Therapeutics to begin a mid-stage clinical trial of its experimental drug GT-02287 in people with Parkinson’s disease.

iShares Micro-Cap ETF

Vanguard Extended Market ETF

Hold rates steady

Cut 25 bps

Hike 25 bps

Fed decision day is here - Kevin Warsh chairs his first FOMC meeting with markets pricing a hold at 3.50%-3.75% but watching for a hawkish shift. Vote on what you expect to be decided today, then drop your prediction for the first rate cut or hike in the comments.

What do you expect the Fed to decide at its FOMC meeting today? 
 
Drop a comment with when you expect the first cut/hike to be.

Current Price	$1.13
Prev Close	$1.19
Open	$1.18
Dividend Yield	0.00%
50-Day Moving Average	$1.62
Beta	1.37
Avg. Volume	428,293.19
PE Ratio	-2.23

52-Week High	$4.34
52-Week Low	$1.11
Market Capitalization	$49.32M
EPS (Annual)	-$0.6115
Price to Book	4.34
Revenue Per Employee	$0.00

Feed

News

Sentiment

Earnings

Fundamentals

Info

GANX Fundamentals